Clinical TrialMay 21, 2026, 08:32 AM
Lantheus to Present New Radiodiagnostic Data at SNMMI Meeting
AI Summary
Lantheus Holdings, Inc. announced it will present new radiodiagnostic data at the 2026 Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting. The presentations include data on the impact of PSMA-PET with Piflufolastat F18 on prostate cancer management and the diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis from a Phase 2 study. These presentations highlight the company's ongoing research and development in radiopharmaceuticals.
Key Highlights
- Lantheus to present new radiodiagnostic data at the 2026 SNMMI Annual Meeting.
- Data on PSMA-PET with Piflufolastat F18 for prostate cancer management to be presented.
- Diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis from a Phase 2 study.
- Prostate cancer data presented in a poster session on June 1, 2026.
- Deep vein thrombosis data presented in an oral session on June 2, 2026.
Price Impact
More from LNTH